LifeVantage (NASDAQ:LFVN) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of LifeVantage (NASDAQ:LFVNGet Rating) in a report issued on Tuesday. The firm set a “strong-buy” rating on the stock.

LifeVantage Stock Performance

LFVN opened at $3.89 on Tuesday. The company has a 50-day moving average of $3.80 and a 200-day moving average of $3.92. The company has a market capitalization of $48.89 million, a P/E ratio of 97.25 and a beta of 1.10. LifeVantage has a 1-year low of $3.46 and a 1-year high of $6.68.

LifeVantage (NASDAQ:LFVNGet Rating) last released its earnings results on Wednesday, November 2nd. The company reported $0.06 earnings per share for the quarter. LifeVantage had a net margin of 0.20% and a return on equity of 9.48%. The company had revenue of $51.77 million during the quarter. As a group, sell-side analysts expect that LifeVantage will post 0.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeVantage

Institutional investors have recently modified their holdings of the business. American Century Companies Inc. boosted its stake in LifeVantage by 30.3% during the 1st quarter. American Century Companies Inc. now owns 46,016 shares of the company’s stock valued at $219,000 after purchasing an additional 10,706 shares during the period. BlackRock Inc. boosted its stake in LifeVantage by 10.5% during the 1st quarter. BlackRock Inc. now owns 249,547 shares of the company’s stock valued at $1,188,000 after purchasing an additional 23,788 shares during the period. Dimensional Fund Advisors LP boosted its stake in LifeVantage by 4.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 271,614 shares of the company’s stock valued at $1,293,000 after purchasing an additional 11,964 shares during the period. State Street Corp boosted its stake in LifeVantage by 7.6% during the 1st quarter. State Street Corp now owns 46,191 shares of the company’s stock valued at $220,000 after purchasing an additional 3,281 shares during the period. Finally, EP Wealth Advisors LLC acquired a new position in LifeVantage during the 1st quarter valued at about $234,000. Institutional investors own 29.69% of the company’s stock.

About LifeVantage

(Get Rating)

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive and immune system function; a line of weight management products under the PhysIQ brand; IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes.

Featured Stories

Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.